Dynavax to Present at the 33rd Annual J.P. Morgan Healthcare Conference
(firmenpresse) - BERKELEY, CA -- (Marketwired) -- 01/12/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2015 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time).
Eddie Gray, Chief Executive Officer of Dynavax, will provide a company overview and update. To access the slide presentation, live webcast, and subsequent archived recording, please visit Dynavax's website at .
Dynavax, a clinical-stage biopharmaceutical company, uses TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine. For more information visit .
Michael Ostrach
Chief Business and Principal Financial Officer
510-665-7257
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 12.01.2015 - 21:05 Uhr
Sprache: Deutsch
News-ID 363812
Anzahl Zeichen: 2998
contact information:
Town:
BERKELEY, CA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 226 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Dynavax to Present at the 33rd Annual J.P. Morgan Healthcare Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
Dynavax Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
